Key facts
- It has raised $200.0M; the latest was Early Stage VC ($200.0M) in Jan 2025.
- Notable investors include Qiming Venture Partners, OrbiMed, Novo Holdings, Blue Owl Capital, SR One Capital Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Windward Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Windward Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Windward Bio
Operator of a drug development company intended to improve outcomes for people living with advanced immunological diseases. The company speeds up the development of a fully human monoclonal antibody that potently binds to the TSLP ligand, enabling users to achieve an extended half-life and effector silencing, and is subcutaneously administered.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2024
- Employees
- 39
- Website
- windwardbio.com/
- Ownership
- Privately Held (backing)
Windward Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Windward Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Windward Bio in its N-PORT filings yet. We sweep new filings monthly.